You're right looking at Healius figures.
Reason why it would be interesting to know if AFR is talking about EBITDA or EBIT.
Just talking about Healius, interesting to see its valuation : EV/EBITDA of 30 x FY 20 (and 24 x FY 19). Perhaps due to a low basis of earnings (strong rebound during Q1 21).
However, most of Healius results come from the diagnostics business, while QScan is more radiology related, if I understood correctly. So I am interested if someone has a better (listed) comparison for Q Scan.
Ann: Infratil 2020 Auckland Investor Day, page-33
Add IFT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.100(0.88%) |
Mkt cap ! $10.92B | |||
| Open | High | Low | Value | Volume |
| $11.67 | $11.67 | $11.30 | $4.694M | 412.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 393 | $11.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.38 | 3048 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IFT (ASX) Chart |